Results 251 to 260 of about 220,321 (314)

Hormone Replacement Therapy Uptake and Discontinuation Trends From 1996‐2023: An Observational Study of the Welsh Population

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To analyse prescribing trends for oral and transdermal hormone replacement therapy (HRT) in Wales from 1996 to 2023, including predictors of discontinuation within one year of initiation. Design Observational study using the Secure Anonymised Information Linkage (SAIL) databank.
Robin Andrews, Arron Lacey, Kate Bache, Emma J. Kidd   +3 more
wiley   +1 more source

Loss of progesterone receptor in smooth muscle cells has no impact on oviductal contractions and preimplantation embryo development†. [PDF]

Biol Reprod
McGlade EA, Mao J, Stephens KK, Rose CN, Lydon JP, Winuthayanon W.   +5 more
europepmc   +1 more source

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer. [PDF]

Front Oncol
Ohara M, Mikami E, Inohana W, Kurosawa T, Nakame A, Sakakibara A, Ichinose Y, Fujimoto A, Nukui A, Asano A, Shimada H, Asai K, Hirasaki M, Yokogawa H, Matsuura K, Ishiguro H, Hasebe T, Fujiuchi N, Osaki A, Saeki T.   +19 more
europepmc   +1 more source

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer. [PDF]

JCO Precis Oncol
Gibson S, Shah F, Parajuli R.
europepmc   +1 more source

Comparative Analysis of the Progesterone Receptor Interactome in the Human Ovarian Granulosa Cell Line KGN and Other Female Reproductive Cells. [PDF]

Proteomics
Foot NJ, Dinh DT, Emery-Corbin SJ, Yousef JM, Dagley LF, Russell DL.   +5 more
europepmc   +1 more source

Breast acinic cell carcinoma with weak progesterone receptor expression: a case report and literature review. [PDF]

Front Oncol
Bai C, Xin X, Yang Y, Qu F, Fan Z.
europepmc   +1 more source

Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer. [PDF]

Ger Med Sci
Kumari B, Lahariya R.
europepmc   +1 more source

Prognostic Impact of Estrogen and Progesterone Receptor Expression across Histological Subtypes and Clinical Factors in Epithelial Ovarian Cancer.

Gynecol Obstet Invest
Gasimli K, Wilke AM, Schmeil I, Gasimli B, Karn T, Becker S, Arsenic R, El-Balat A.   +7 more
europepmc   +1 more source